Tag Archives: any age

Myasthenia Gravis Awareness

Myasthenia Gravis (pronounced My-as-theen-ee-a Grav-us) comes from the Greek and Latin words meaning “grave muscular weakness.” The most common form of MG is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. The prevalence of MG in the United States is estimated to be about 20/100,000 population. However, MG is probably under diagnosed and the prevalence may be higher. Myasthenia Gravis occurs in all races, both genders, and at any age. MG is not thought to be directly inherited nor is it contagious. It does occasionally occur in more than one member of the same family.

The voluntary muscles of the entire body are controlled by nerve impulses that arise in the brain. These nerve impulses travel down the nerves to the place where the nerves meet the muscle fibers. Nerve fibers do not actually connect with muscle fibers. There is a space between the nerve ending and muscle fiber; this space is called the neuromuscular junction.

When the nerve impulse originating in the brain arrives at the nerve ending, it releases a chemical called acetylcholine. Acetylcholine travels across the space to the muscle fiber side of the neuromuscular junction where it attaches to many receptor sites. The muscle contracts when enough of the receptor sites have been activated by the acetylcholine. In MG, there can be as much as an 80% reduction in the number of these receptor sites. The reduction in the number of receptor sites is caused by an antibody that destroys or blocks the receptor site.

Antibodies are proteins that play an important role in the immune system. They are normally directed at foreign proteins called antigens that attack the body. Such foreign proteins include bacteria and viruses. Antibodies help the body to protect itself from these foreign proteins. For reasons not well understood, the immune system of the person with MG makes antibodies against the receptor sites of the neuromuscular junction. Abnormal antibodies can be measured in the blood of many people with MG. The antibodies destroy the receptor sites more rapidly than the body can replace them. Muscle weakness occurs when acetylcholine cannot activate enough receptor sites at the neuromuscular junction.

This Information and more can be found at The Myasthenia Gravis Foundation of America’s website

November is National Epilepsy Awareness Month

Epilepsy affects about 2 million people in the United States and is characterized by recurrent, unprovoked seizures. Delayed recognition of these seizures and inadequate treatment increases the risk for additional seizures, disAbility, decreased health-related quality of life and, in rare instances, death.

Although epilepsy can occur at any age, the condition is more likely to begin among children less than 2 years of age and adults older than 65 years. As do many who live with other chronic disorders, those with epilepsy often face challenges related to managing epilepsy treatment, symptoms, disAbility, lifestyle limitations, emotional stress, and stigma.

CDC’s Managing Epilepsy Well (MEW) Network is composed of individuals interested in improving the care of people with epilepsy. MEW Network members, including representatives from U.S. universities, community-based organizations, and CDC are working together to develop and test self-management programs and tools that help people with epilepsy better manage their disorder and improve their quality of life.

MEW programs available to communities include WebEase, UPLIFT, and PEARLS. WebEase (Epilepsy Awareness Support and Education) is an Internet self-management program designed to improve medication adherence, stress management, and sleep. UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is an Internet and telephone program that combines cognitive behavioral therapy with mindfulness to treat depression in people with epilepsy. PEARLS (Program to Encourage Active Rewarding Lives) is a home-based, collaborative-care depression treatment program for adults with epilepsy.

Interventions that are currently being tested by MEW network researchers include a self-management program that combines self-regulation and social support for adults with refractory epilepsy; an electronic decision-support system for clinics to improve self-management communication and behavior; and a consumer-driven self-management program. New projects include a telephone intervention for rural dwelling adults with epilepsy and cognitive impairment, and self-management training for adults with epilepsy and co-existing serious mental illness.